Keyphrases
Liver Transplantation
100%
Hepatocellular Carcinoma
40%
Liver Transplant Recipients
30%
Risk Factors
27%
European Liver Transplant Registry
23%
Pneumocystis Jirovecii
23%
Transplantation
23%
MELD Score
19%
First Year
17%
Retransplantation
15%
Pretransplant
14%
Graft Loss
14%
Hazard Ratio
12%
Orthotopic Liver Transplantation
11%
Length of Stay
10%
Confidence Interval
10%
Postoperative Complications
9%
Microvascular Invasion
9%
Tumor Cells
9%
Renal Transplant Recipients
8%
Clavien-Dindo Classification
8%
Peritoneal Tumor
7%
Colorectal Liver Metastases
7%
Cause of Death
7%
Circulating Tumor DNA (ctDNA)
7%
Fast-track Programme
7%
Enterococcal Infections
7%
Risk Prognosis
7%
Prospective Cohort Study
7%
Caval Replacement
7%
Liver Surgery
7%
Locoregional Treatment
7%
Primary Sclerosing Cholangitis
7%
Meta-analysis
7%
Ethylenediaminetetraacetic Acid
7%
Metabolic Syndrome
7%
Peritoneal Cytology
7%
Hyaluronic Acid
7%
Donor Hepatectomy
7%
Allograft Dysfunction
7%
Gastroesophageal Junction Cancer
7%
End-stage Renal Disease
7%
Prognostic Score
7%
First Week
7%
Systematic Meta-analysis
7%
Renal Function
7%
Rapid Decline
7%
Glomerular Filtration Rate
7%
Enhanced Recovery after Surgery (ERASĀ®)
7%
Neoadjuvant Chemotherapy
7%
Medicine and Dentistry
Liver Transplantation
93%
Liver Graft
45%
Hepatocellular Carcinoma
39%
Malignant Neoplasm
20%
Cohort Analysis
17%
Pneumocystis Pneumonia
15%
Pneumocystis Jirovecii
15%
Transplantation
13%
Graft Failure
13%
Hazard Ratio
12%
Overall Survival
11%
Model For End Stage Liver Disease Score
10%
Postoperative Complication
9%
Hepatectomy
9%
Neoplasm
9%
Kidney Graft
9%
Tumor Cell
9%
Peritoneum Tumor
7%
Meta-Analysis
7%
Systematic Review
7%
Biological Marker
7%
Kidney Function
7%
Enhanced Recovery After Surgery
7%
Restylane
7%
Metabolic Syndrome
7%
Enterococcal Infection
7%
Glomerular Filtration Rate
7%
Prospective Cohort Study
7%
Allograft
7%
Edetate Chromium Cr 51
7%
Circulating Tumor DNA
7%
Primary Sclerosing Cholangitis
7%
Cause of Death
7%
Gastroesophageal Junction
7%
Population
7%
Cytotechnology
7%
Liver Surgery
7%
Neoadjuvant Chemotherapy
7%
Colorectal Liver Metastasis
7%
End Stage Renal Disease
7%
Proportional Hazards Model
7%
Liver Cirrhosis
6%
Milan Criteria
6%
Retransplantation
6%
Bloodstream Infection
5%
Ischemia
5%
Recurrent Disease
5%